"Advancement In Understanding The Pathophysiology And Treatment Strategies Of Gestational Diabetes Mellitus: A Comprehensive Review"

Riyaz Ahmad Bhat[1*], Imtiyaz Hussain[2], Patil Hanumanthrao[3], Patil Rajesh Kumari[4]

[1*,2] Pharm.D (Student), Adesh Institute of Pharmacy and Biomedical Sciences, Adesh University, Bathinda, Email: bhatriyaz767@gmail.com
[3]Professor & Principal (Pharmacy Practice,) Adesh Institute of Pharmacy and Biomedical Sciences,Adesh University, Bathinda, Email: hcpatil@gmail.com
[4]Professor & HoD , Department of Pharmacy Practice, Adesh Institute of Pharmacy and Biomedical Sciences, Adesh University, Bathinda, Email: rkpatil3014@gmail.com

***Corresponding Author:** Riyaz Ahmad Bhat
*Pharm.D (Student), Adesh Institute of Pharmacy and Biomedical Sciences, Adesh University, Bathinda, Email: bhatriyaz767@gmail.com

Abstract:
When pregnant women with no history of diabetes develop chronic hyperglycaemia it is known as gestational diabetes mellitus (GDM),Aserious pregnancy disease, Pancreatic beta-cell-induced decreased glucose tolerance is the cause of this hyperglycaemia.Risks for Gestational diabetes mellitus usually are overweight, being fatty, Maternalold age or having any kind of history in a family. Type 2 diabetes, macrosomia, maternal cardiovascular disease, and challenges with new-born delivery are all side effects of GDM. Additionally, there is a long-term chance that the child may become obese, acquire type 2 diabetes, or experience cardiovascular problems.Although there are a few management strategies, including the use of insulin and alterations to one's lifestyle, there is yet no proven cure or prophylactic measure. One reason for this is the lack of knowledge about the molecular mechanisms underlying GDM.This review provides information on the aetiology, impacts,kinds of gestational diabetes, risk factors, and several procedures for detecting Hyperglycaemia. The outcomes of hyperglycaemia or high blood sugar level on the mother and the unborn child will also be covered. Methods to oral, nutritional, and exercise monitoring of blood sugar Prescription medicines and insulin injections are covered.

Keywords: Gestational diabetes; pregnancy; pathophysiology; Management; of GDM; diagnosis; maternal and neonatal effects (implications); risk factors

INTRODUCTION

Hyperglycemia is characterised as carbohydrate intolerance related to glucose galactose of any severity that begins or is first seen during gestation. Gestational diabetes mellitus (GDM), a metabolic condition, is sometimes referred to as hyperglycemia. One in every seven births may be impacted internationally. The condition known as GDM, or hyperglycemia, is associated with problems during pregnancy and childbirth such as high blood pressure, preeclampsia, immaturity, foetal macrosomia, shoulder dystocia, and birth trauma. C-sections are more common, and there is a higher risk of neonatal and prenatal mortality. Other newborn problems include respiratory distress syndrome (RDS), hypoxia, and hypoglycemia. Even in the latter years of the mother's and child's lives, GDM may be viewed negatively**.**Women who have metabolic syndrome and type 2 diabetes mellitus (T2DM) are more likely to develop gestational diabetes mellitus (GDM), which is characterised by spontaneous hyperglycemia connected to pregnancy. One frequent pregnancy complication is hyperglycemia. Despite the fact that GDM normally goes away after childbirth, it may have long-term effects on the mother's health, including an elevated risk of type 2 diabetes (T2DM) and cardiovascular disease (CVD), as well as a future risk of obesity, CVD, T2DM, and/or GDM in the kid. (1) Clinically, GDM may have an impact on a woman's postpartum and perinatal outcomes.Pregnant women with GDM face increased risks for perinatal complications such as preeclampsia, Caesarean sections, macrosomia, infantile, and hyperbilirubinemia. (11) Exercise, in particular supervised aerobic and/or resistance training, is a useful adjunct therapy for the management of type 2 diabetes mellitus because it enhances glucose uptake and improves insulin sensitivity. (12) It's crucial to bear in mind that insulin sensitivity changes in two stages in healthy pregnant women: initially, it rises dramatically, and as the pregnancy progresses, it starts to fall noticeably.(1) The entire health of the population suffers from this generational or genetic cycle of obesity and diabetes. Currently, there are no widely accepted treatments or preventative strategies for GDM, with the exception of lifestyle changes (diet and exercise) and occasionally insulin therapy, which is only partially helpful because insulin resistance is commonly present. Drugs like glyburide and metformin have affects on the mother and the foetal' safety. Consequently, there is a need for innovative medicines that are secure, efficient, and simple to use. The pathophysiology of GDM must be understood in order to develop such treatments. Risk factors and

glucose regulation during gestation should be taken into account in order to appropriately understand the pathophysiology of GDM. (2)

Glucose Regulation in Pregnancy:
In order to meet the demands of the developing baby, the mother's body goes through a variety of physiological changes over the course of a healthy pregnancy. Modifications to the respiratory, metabolic, hematologic, and renal systems are among them. Significant modifications are made to insulin's metabolic sensitivity. Insulin sensitivity fluctuates throughout gestation according to the needs of pregnancy. An early pregnancy causes an increase in insulin sensitivity, which encourages the absorption of glucose into adipose storage to prepare for a later pregnancy's energy requirements.(21) Although the progression of pregnancy encourages insulin resistance, there is an increase in local and placental hormones such as oestrogen, progesterone, leptin, cortisol, placental lactogen, and placental growth hormone. (22) As a result, blood sugar levels have slightly increased. This high blood sugar level can be easily transported via the placenta to aid in the development of the embryo. This modest form of insulin resistance also encourages endogenous glucose synthesis and fat oxidation, which raise blood sugar levels and free fatty acid concentrations even more. The fact that gestational sensitivity swiftly recovers to its normal range in the days following the mother's delivery suggests that placental hormones play a substantial role during this occurrence.(2)

FORMS OF GESTATIONAL DIABETS MELLITUS:
The three different types of glucose intolerance mellitus that have been identified as occurring outside of pregnancy are type 1, a form of autoimmune disease; type 2, a result of insulin resistance; and type 3, which develops as a result of gene mutations or exocrine pancreatic abnormalities.(23) Most instances of GDM present with beta-cell dysfunction against a background of chronic insulin resistance, to which the usual insulin resistance of pregnancy is mostly additive. There is evidence that each of the three circumstances can cause GDM. Because of this, pregnant women with the condition frequently have greater levels of insulin resistance than pregnant women who are healthy, which causes a reduction in glucose absorption and an increase in glucose production.FFA in great quantities. It is believed that the main factor causing beta-cell degeneration, which ultimately wears out the cells, is increased insulin production in response to excessive energy consumption and insulin resistance. Due to the pathologies of the two disorders closely resembling those of T2D, there has been great debate regarding whether they should be considered to be etiologically identical.(3)

Etiology:
The mother's metabolism alters noticeably throughout pregnancy. The early stages of these changes, which are primarily anabolic, result in a gradual increase in the amount of maternal adipose tissue, whereas the late stages of pregnancy, which are catabolic, result in increased lipolysis, higher levels of glycemia, insulinemia, postprandial fatty acids, and decreased maternal fat stores. These alterations are brought on, at least in part, by hormones and other mediators produced by the placenta, which encourage the formation of peripheral insulin resistance, a physiological condition. (20)

RISK FACTORS:
Gestational diabetes mellitus is caused by a number of risk factors. Numerous variables have been identified by epidemiological studies as hazards for developing or initiating hypoglycemia. The mother's advanced age, also known as over maternal age, any prior family history of type 2 diabetes mellitus, and the race she belongs to may be some of these variables.(9)

AGE:
A greater prevalence of GDM has been linked to maternal ages over 40. Those over 40 had a risk of GDM that was more than twice as high as that of those under 30. GDM seems to be more prevalent in mothers carrying male foetuses. (9)

Ethnicity and geography:
The prevalence estimates of GDM in various countries differed noticeably regardless of whether identical diagnostic standards were used. Shows that some of the variability may be due to differences in the distributions of intrinsic traits among the research populations. In nations with multiethnic populations, including Australia, the United States, and Canada, substantial discrepancies in the frequency of GDM across ethnic communities have also been noted. For instance, throughout northern California, the prevalence of GDM was lowest among African-American women and non-Hispanic white women and greatest among Asians and women from the Philippines. Women from South Asia had a risk of developing GDM that was more than four times greater than that of women from either Australia or New Zealand. Variations in body adiposity, lifestyle (diet and physical activity), and genetic susceptibility are among the main risk factors for GDM. These factors most likely have an impact on ethnic disparities. (2)

Modifiable lifestyle factors:
Being overweight or obese is the major risk factor for GDM before pregnancy. regardless of the BMI before pregnancy, along with additional risk factors. An increased risk of GDM is associated with maternal smoking and cigarette use

during pregnancy.The risk of GDM both before and during pregnancy is reduced by exercise. A number of dietary variables also affect the possibility of GDM. (7)As of now, it is unable to draw any firm conclusions on how particular dietary elements during pregnancy might contribute to the emergence of GDM. The chance of developing GD may, however, appear to be raised by increased dietary fat intake during pregnancy and low plasma levels of vitamin D and C in the early stages of pregnancy.(15)Numerous dietary traits that are unrelated to body fat and physical activity have been discovered in comprehensive qualitative research based on the diet prior to becoming pregnant, including a higher intake of sugar-sweetened beverages, potatoes, fried meals, haemoglobin, animal fat, and protein.Diets heavy in animal oil and protein while poor in carbohydrates, as well as the usual "Western" eating habits of high intake of red meat, processed meat, refined grain products, sweets, French fries, and pizza, all increase the likelihood of getting GDM. (4)

New risk factors:
Environmental, behavioural, and dietary factors, as well as lifestyle and dietary choices, may all have an impact on the likelihood of developing GDM. Perfluorooctanoic acid and polybrominateddiphenyl ethers are two examples of long-term organic pollutants and disruptors of the endocrine system that have been linked to an increased threat of developing GDM. Additionally, several prospective studies have linked depression in the first and second trimesters to an increased risk of gestational diabetes. (4)

Genetic influences:
Since it is thought that genetic inheritance plays a role in the aetiology of GDM, research investigating the relationships between certain genetic variables and GDM is scarce, and the results of those that have been conducted have been inconsistent. Nine single-nucleotide polymorphisms were also shown to be associated with an increased risk of developing GDM by their minor alleles for seven genes. These are the majority that have a role in controlling the release of insulin.(5)

Gestational diabetes mellitus Pathophysiology:
Understanding the pathophysiology of GDM might benefit from investigating lipids as well as how these work, although lipidomic investigations in GDM are relatively uncommon compared to wider metabolomic research. (14)

Overview of GDM's pathogenesis:
An overview of the pathophysiology of GDM Since beta-cell dysfunction commonly leads to GDM, decreased activity of beta cells as well as elevated tissue levels of insulin are both contributing factors to the disease's aetiology. In most instances, these irregularities are visible prior to conception and can occur, raising the possibility of Type 2 diabetes after birth. Also involved in or impacted by GDM are additional organs and systems. They are the placenta, muscle, fat, brain, liver, and muscle. (2)

B-Cell Dysfunction:
In response to a carbohydrate demand, beta cells' main job is to accumulate and deliver glucagon. The inability of beta cells to accurately sense levels of glucose in the blood or to respond by releasing adequate insulin in response is known as cell dysfunction. (24) It is believed that beta-cell dysfunction results from sustained, elevated insulin synthesis in reaction to long-term fuel excess. Beta-cell dysfunction, however, may be caused by a variety of complicated pathways (25, 26). The phases in the process that can go awry include the creation of pro-insulin, modifications following translation, granule retention, monitoring blood glucose levels, and the intricate machinery behind granule exocytosis.Keeping granules in storage, checking blood sugar levels, or understanding the intricate principles of granule digestion.In reality, many of the genes associated with GDM vulnerability, including glucokinase and the potassium voltage-gated channel KQT-like (Gck), are essential for the function of beta cells. Only under conditions of physiological strain, such as while pregnant, may minor defects in the beta-cell's machinery be detected. The expression "glucotoxicity" refers to how glucose directly causes cell death. For this reason, once beta-cell malfunction becomes apparent, a vicious cycle of high blood sugar levels, resistance to insulin, and further dysfunction in beta cells is set into action. (8)

Insulin resistance:
At the molecular level, the fourth glucose transporter (GLUT4), the key transporter in charge of providing blood sugar to the cell to be used as energy, cannot freely move across the plasma membrane, which results in insulin resistance. Insulin resistance develops when cells stop responding to insulin effectively. (27)(27) althy pregnancy has a higher rate of insulin-stimulated glucose absorption than GDM16. However, insulin receptor abundance is typically unaltered. Insulin signalling is attenuated by reduced tyrosine or enhanced serine/threonine phosphorylation of the insulin receptor. Insulin receptor substrate (IRS)-1, phosphatidylinositol 3-kinase (PI3K), and GLUT4 have all been linked to altered insulin signalling downstream regulator expression and/or phosphorylation in GDM.(28) Many of these molecular alterations continue to occur after delivery. The insulin signalling process is considered to be impacted by a number of the previously mentioned GDM risk factors. GDM.instance, saturated fatty acids induce PKC and inhibit PI3K, IRS-1, and tyrosine kinase, increasing the quantities of diacylglycerol present intracellularly in myocytes.(8)

Liver:
In other words, GDM, or hyperglycemia, is interrelated with increased hepatic glucose manufacturing, which is known as gluconeogenesis. Compared to when a person is starving, glucose synthesis is more effectively controlled when a person is fed.The major part of the glucose that is absorbed by the liver does not utilise insulin; hence, it is not entirely believed that this is a result of impaired glucose sensing brought on by insulin resistance. These effects might be brought on by components, such PI3K, that are shared by the pathways that control gluconeogenesis and the insulin signalling pathway. Increased protein consumption and muscle breakdown could both be sped up by providing too much gluconeogenesis substrate. However, neither T2DM nor GDM seem to be largely regulated by the liver.(2)

Neurohormonal Networks:
According to several studies, neurohormonal disruption plays a part in the aetiology of diseases like GDM that are resistant to insulin. This intricate system of peripheral, such as satiety and hunger hormones, and central, such as brain regions controlling cognitive, visual, and "reward" trigger signals, regulates hunger, satiety, and basal metabolic rate. These have an impact on GDM through altering obesity and glucose intake. The circadian clock tightly regulates this network, which may help explain why individuals with severe sleep disturbances or shift workers have a higher incidence of GDM.(8)

Leptin:
Leptin is a chemical messenger or we can say the hormoneprimarily produced by adipose cells the main function of this is to regulate energy balance in the body response to fuel reserves.It effects mostly neurons of hypothalamic such as arcuate nucleus, which reduces appetite and increases energy expenditure. The appetite-stimulating neuropeptide and agouti-related peptide as well as the anorexigenic polypeptide pro-opiomelanocortinare all particularly suppressed by leptin.

Adiponectin:
Similar to leptin, adipocytes primarily release the hormone adiponectin. Despite being low in obese people, plasma adiponectin levels are negatively linked with fatty tissue density. It's also believed that GDM patients have lower adiponectin levels. In contrast to leptin, adiponectin is more strongly linked to insulin resistance than obesity. This demonstrates that adiponectin contributes significantly to the aetiology of GDM, independent of fat.

Adipose tissue:Adipose tissue was once thought to be an inactive energy reserve, but the discovery of leptin changed this perception and recognised adipose tissue as a crucial endocrine organ. Adipose tissue actively secretes adipokines and cytokines, which have broad metabolic impacts in addition to ensuring that energy is distributed safely.(2)

Cardiac and skeletal muscle:
In the past it was believed that skeletal muscle insulin resistance was the root cause of T2DM. To protect against metabolic stress and steatosis skeletal muscle insulin resistance is thought to be caused by hyperglycaemia at the moment. (29) Even a short period of overeating causes the development of insulin resistance in the cardiac and skeletal muscles, which directs the extra energy to fat tissue.(30)

Obesity:
The most significant disease-related risk factor that can be changed is obesity, and because it is becoming more and more prevalent throughout the world, it poses a special public health concern. The risk variables that are both inherited and environmental show the possibility of complicated molecular pathways underlying GDM.(18)

Oxidative stress:
Oxidative stress also known as free radicle damage which is raiseddue to loss of balance between pro-oxidants and antioxidants in cells. Cells which are harmed by the Oxidative stress can have an impact on nitrogenous compounds such as proteins, fats and other substances. Deoxyribonucleic acid, commonly known as nucleic acid, may be the cause of a number of disorders, including GDM (also known as hyperglycemia). Hyperglycemia is associated with free radical damage, and women with GDM or hyperglycemia have been found to produce excessive amounts of reactive oxidant entities and reactive nitrogen forms as well as to have deteriorated mechanisms that scavenge free radicals. Reactive oxygen species obstruct the absorption of insulin-stimulated glucose via GLUT4 and IRS-1.(6)The onset of oxidative stress (OS) during gestation may be influenced by elevated iron levels as well as a hyperglycemic environment. OS takes place when the fragile equilibrium involving the synthesis of antioxidant neutralising species, such as NADPH with glutathione (GSH), and the generation of reactive oxygen species (ROS), is disturbed.Hyperglycemia increases OS levels via a number of metabolic processes. In contrast, a high intake of iron might subject women to higher levels of oxidative damage to lipids and protein carboxylation owing to cellular reactive oxygen species (ROS) formation. For instance, it creates an excess of ROS by depleting antioxidants.(17)

Energy Storage:
For metabolic stability, adipose tissue's storing ability is essential. Two extremes illustrate this.Certain obese people with an abundance of white adipose tissue do not acquire severe metabolic syndrome, even though the illness is characterised by uncommon conditions in which the tissue is absent.Patients who are non-diabetic with obesity respond to a fuel surplus by growing enough adipose tissue, which aids in the maintenance of stable blood sugar levels, enough beta-cell compensation, and the prevention of long-term insulin resistance. This protects crucial organs from the tissue damage that fatty acids and glucose induce.(8)

Transport through the placenta also known as placental transport:
The placenta of the growing child has an impact on the resistance to insulin throughout pregnancy. via the release of cytokines and hormones.In addition, throughout GDM, the placenta, which serves as an obstruction between the mother's environment and that of the foetus, is susceptible to hyperglycemia and its effects. This might have an impact on how the placenta transports lipids, sugar, and amino acids. (6)

Diagnosis:
Monitoring of glucose:
As soon as GDM is identified, patients should begin monitoring the glucose levels in their blood, starting with fasting levels and one- or two-hour postprandial readings. The amount of sugar in the blood after meals should be under or equal to 120 mg/dL two hours after eating, 140 mg/dL one hour after eating, and 95 mg/dL or less during fasting.One or two hours after eating should be monitored, although there is no evidence to suggest that one is preferable to the other. Less frequent glucose testing is recommended for women with GDM who successfully control their disease with diet and exercise.(5)

MANAGEMENT:
Currently, there are therapeutic possibilities that involve modifying the way one lives, such as incorporating more exercise (PA) and improving diet quality through the use of nutritional counselling.(13)

CONTROLLING YOUR OWN GLUCOSE:
The goal of medical treatment for pregnant women is to maintain their blood sugar levels within the range of reference. Before the end of the seventies, when self-glucose monitoring became readily available, women with GDM had to visit labs to have their blood glucose levels checked.As an outcome, it was probable that the findings were insufficiently representative of what was happening within the person's daily routine. This indicated that the glucose test day was out of the ordinary. Glucose testing was made possible by the development of test strips and reflectance metres, which could fit into almost any living space.First, research on healthy, non-diabetic pregnant women served as the foundation for the objectives for glucose management in diabetes pregnancy. Other investigations found that diabetes pregnancies with mean glucose concentrations maintained within that reference range had decreased perinatal mortality rates as well.(16)

DIET:
Medical dietetics is the initial step in obtaining euglycemia in gestational diabetes. The food regimen is specially created for the patient based on their height and weight and is based on both the nutritional requirements of pregnancy and the concepts of a diabetic diet.The food plan also aims to prevent hyperglycemia and assist the mother in gaining the right amount of weight. Because they have a tendency to produce sharp increases in blood glucose levels, refined foods and intense candies are discouraged for women with GDM. Obese individuals with GDM may or may not need to adhere to severely low-calorie diets.(10)

Insulin:
For women with poorly managed blood glucose levels, subcutaneous insulin injections are often the next step in treatment after lifestyle modification. Insulin is useful for controlling GDM when paired with lifestyle changes. As insulin 132 pumps have not been extensively researched for usage in the context of GDM, this is one of the primary drawbacks of insulin therapy. This can increase anxiety during the sometimes already stressful 134 time of pregnancy and calls for health 133 professiona knowledge, careful adherence, and planning.In addition, insulin cannot be administered as a prophylactic measure due to the significant risk of causing hypoglycemia. Therefore, there is a need for prevention measures even though insulin is the most effective treatment for poorly controlled GDM.(16)

ORAL AGENT:
Oral antidiabetic medicines are the second line treatment options for type 2 diabetes and are often initiated when medically prescribed nutrition has failed to sufficiently control blood glucose levels.Because insulin, the internationally recognised gold standard, needs subcutaneous injections, which can be painful and unsettling for patients, there has been a lot of interest in their usage during pregnancy.The most frequently used oral medications fall into two categories. Sulfonylureas stimulate the pancreas release and production of insulin; they may result in hypoglycaemia and are only useful when the pancreas is able to produce insulin. As a result, they are not applied to females with type 1 diabetes. It has been demonstrated that first-generation sulfonylureas can pass the placenta and may lead to neonatal hypoglycaemia.

Due to the ease with which glucose can cross the placenta, maternal hyperglycaemia, whether caused by pre-existing diabetes or by gestational diabetes, results in foetal hyperglycaemia. A higher production and release of insulin occurs in the foetal pancreas in response to elevated glucose levels.Known together as diabetic fetopathy, this foetal hyperinsulinemia is what causes the majority of foetal issues encountered in diabetic pregnancy. One of the more noticeable issues is foetal macrosomia, which is thought to be related to the foetal insulin's ability to promote growth. Infants are more likely to experience shoulder dystocia after delivery due to the disproportional, excessive growth that results in a lot of subcutaneous fat and broad shoulders. In the early neonatal period, when they are abruptly cut off from the maternal source of glucose while still having high concentrations of circulating insulin, hyperinsulinemic infants are vulnerable to hypoglycaemia. These infants also experience hypocalcaemia, hyperbilirubinemia, and plethora as issues.(7)

IMPLICATIONS OF GESTATIONAL DIABETES MELLITUS:

Due to the ease with which glucose can cross the placenta, maternal hyperglycemia, whether caused by pre-existing diabetes or gestational diabetes, results in foetal hyperglycemia. A higher production and release of insulin occur in the foetus pancreas in response to elevated glucose levels.Known together as diabetic fetopathy, this foetal hyperinsulinemia is what causes the majority of foetal issues encountered in diabetic pregnancy.Foetal macrosomia, which is believed to be connected to the capacity of foetal insulin to stimulate development, is one of the most obvious problems. Due to their disproportional, excessive development, which leaves them with broad shoulders and a lot of fat under their skin, infants are more prone to have shoulder dystocia following delivery.Premature newborns are more likely to have respiratory distress syndrome and other prematurity-related conditions if their mothers have gestational diabetes.(9)Hyperinsulinemicnewborns are susceptible to hypoglycemia during the immediate period of development whenever they're abruptly cut off from the mother's supply of glycogen while still having high quantities of plasm insulin.These infants also experience hypocalcaemia, hyperbilirubinemia, and plethora as issues.The mother is also affected by gestational diabetes.Preeclampsia and caesarean deliveries are more frequent in those with undetected and uncontrolled GDM, yet both conditions are preventable with early identification and treatment. Although gestational diabetes in and of itself may not necessitate caesarean delivery, its complications might. Preeclampsia, for instance, may call for an early birth by inducing labour before the cervix is ripe increasing the likelihood of a caesarean surgery.(7)Theoretically, being in an intrauterine environment with diabetes causes excessive foetal growth. Maternal insulin cannot cross the placenta biologically, whereas maternal glucose can. The foetal pancreas responds to this rise in glucose load by producing more insulin, which in turn encourages foetal growth and the development of obesity.(19)

CONCLUSION:

Maintaining glucose homeostasis is important during pregnancy because it involves a high level of metabolic activity.Despite ongoing disagreement over diagnostic criteria, GDM is the diagnosis used when pregnant women are discovered to have hyperglycemia. It is probable that the processes underlying the formation of GDM are complex and have developed over a long period of time. Genetic, epigenetic, and environmental factors are likely to all play a role in the disease's onset. However, in the vast majority of instances, pancreatic betacells are unable to make up for a persistent fuel surplus, which eventually results in insulin resistance, hyperglycaemia, and an increased supply of glucose to the developing foetus.Those with GDM are more likely to have diabetes than those without GDMhad a more than 7 fold increased chance of acquiring postpartum diabetes. Previous studies have found a number of risk factors for postpartum diabetes, including age, prenatal glucose level, family history of diabetes, obesity, physical activity, and breastfeeding.

REFERENCES:

1. Dłuski, D. F., Wolińska, E., &Skrzypczak, M. *(2021). Epigenetic changes in gestational diabetes mellitus. International Journal of Molecular Sciences, 22(14), 7649.*
2. Plows, J. F., Stanley, J. L., Baker, P. N., Reynolds, C. M., & Vickers, M. H. *(2018). The pathophysiology of gestational diabetes mellitus. International journal of molecular sciences, 19(11), 3342.*
3. Buchanan, T. A., & Xiang, A. H. *(2005). Gestational diabetes mellitus. The Journal of clinical investigation, 115(3), 485-491.*
4. McIntyre, H. D., Catalano, P., Zhang, C., Desoye, G., Mathiesen, E. R., &Damm, P. *(2019). Gestational diabetes mellitus. Nature reviews Disease primers, 5(1), 47.*
5. Garrison, A. *(2015). Screening, diagnosis, and management of gestational diabetes mellitus. American family physician, 91(7), 460-467.*
6. Lappas, M., Hiden, U., Desoye, G., Froehlich, J., Mouzon, S. H. D., &Jawerbaum, A. *(2011). The role of oxidative stress in the pathophysiology of gestational diabetes mellitus. Antioxidants & redox signaling, 15(12), 3061-3100.*
7. Starikov, R., Bohrer, J., Goh, W., Kuwahara, M., Chien, E. K., Lopes, V., &Coustan, D. *(2013). HemoglobinA1c in pregestational diabetic gravidas and the risk of congenital heart disease in the fetus. Pediatric cardiology, 34, 1716-1722.*
8. Berberoglu, Z. *(2019). Pathophysiology of gestational diabetes mellitus. Diabetes.*
9. Teh, W. T., Teede, H. J., Paul, E., Harrison, C. L., Wallace, E. M., & Allan, C. *(2011). Risk factors for gestational diabetes mellitus: implications for the application of screening guidelines. Australian and New Zealand Journal of Obstetrics and Gynaecology, 51(1), 26-30.*

10. Denney, J. M., & Quinn, K. H. *(2018). Gestational diabetes: underpinning principles, surveillance, and management. Obstetrics and Gynecology Clinics, 45(2), 299-314.*
11. Harrison, A. L., Shields, N., Taylor, N. F., &Frawley, H. C. *(2016). Exercise improves glycaemic control in women diagnosed with gestational diabetes mellitus: a systematic review. Journal of physiotherapy, 62(4), 188-196.*
12. Mijatovic-Vukas, J., Capling, L., Cheng, S., Stamatakis, E., Louie, J., Cheung, N. W., & Flood, V. M. *(2018). Associations of diet and physical activity with risk for gestational diabetes mellitus: a systematic review and meta-analysis. Nutrients, 10(6), 698.*
13. Alesi, S., Ghelani, D., Rassie, K., &Mousa, A. *(2021). Metabolomic biomarkers in gestational diabetes mellitus: A review of the evidence. International Journal of Molecular Sciences, 22(11), 5512*.
14. Silva-Zolezzi, I., Samuel, T. M., &Spieldenner, J. *(2017). Maternal nutrition: opportunities in the prevention of gestational diabetes. Nutrition reviews, 75(suppl_1), 32-50.*
15. Plows, J. F., Reynolds, C. M., Vickers, M. H., Baker, P. N., & Stanley, J. L. *(2019). Nutritional supplementation for the prevention and/or treatment of gestational diabetes mellitus. Current Diabetes Reports, 19, 1-15.*
16. Zaugg, J., Melhem, H., Huang, X., Wegner, M., Baumann, M., Surbek, D., & Albrecht, C. *(2020). Gestational diabetes mellitus affects placental iron homeostasis: Mechanism and clinical implications. The FASEB Journal, 34(6), 7311-7329.*
17. Johns, E. C., Denison, F. C., Norman, J. E., & Reynolds, R. M. *(2018). Gestational diabetes mellitus: mechanisms, treatment, and complications. Trends in Endocrinology & Metabolism, 29(11), 743-754.*
18. Chen, L., Mayo, R., Chatry, A., & Hu, G. *(2016). Gestational diabetes mellitus: its epidemiology and implication beyond pregnancy. Current Epidemiology Reports, 3(1), 1-11*
19. Chiefari, E., Arcidiacono, B., Foti, D., &Brunetti, A. *(2017). Gestational diabetes mellitus: an updated overview. Journal of endocrinological investigation, 40, 899-909.*
20. Di Cianni, G., Miccoli, R., Volpe, L., Lencioni, C., & Del Prato, S. *(2003). Intermediate metabolism in normal pregnancy and in gestational diabetes. Diabetes/metabolism research and reviews, 19(4), 259-270.*
21. Catalano, P. M., Tyzbir, E. D., Roman, N. M., Amini, S. B., & Sims, E. A. *(1991). Longitudinal changes in insulin release and insulin resistance in nonobese pregnant women. American journal of obstetrics and gynecology, 165(6), 1667-1672.*
22. American Diabetes Association. *(2018). 2. Classification and diagnosis of diabetes: standards of medical care in diabetes—2018. Diabetes care, 41(Supplement_1), S13-S27.*
23. Weir, G. C., Laybutt, D. R., Kaneto, H., Bonner-Weir, S., & Sharma, A. *(2001). Beta-cell adaptation and decompensation during the progression of diabetes. Diabetes, 50(suppl_1), S154.*
24. DeFronzo, R. A. *(2009). From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes, 58(4), 773-795.*
25. Zraika, S., Hull, R. L., Verchere, C. B., Clark, A., Potter, K. J., Fraser, P. E., & Kahn, S. E. *(2010). Toxic oligomers and islet beta cell death: guilty by association or convicted by circumstantial evidence?. Diabetologia, 53, 1046-1056.*
26. Catalano, P. M. *(2014). Trying to understand gestational diabetes. Diabetic Medicine, 31(3), 273-281.*
27. Barbour, L. A., McCurdy, C. E., Hernandez, T. L., Kirwan J. P., Catalano, P. M., & Friedman, J. E. *(2007). Cellular mechanisms for insulin resistance in normal pregnancy and gestational diabetes. Diabetes care, 30(Supplement_2), S112-S119.*
28. Kelley, D. E., Goodpaster, B. H., &Storlien, L. *(2002). Muscle triglyceride and insulin resistance. Annual review of nutrition, 22(1), 325-346.*
29. Prentki, M., & Nolan, C. J. (2006). Islet β cell failure in type 2 diabetes. The Journal of clinical investigation, 116(7), 1802-1812.